First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued (TRAXV) - Net Assets
Based on the latest financial reports, First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued (TRAXV) has net assets worth $- USD as of . Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($-) and total liabilities ($-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Explore cash flow conversion of First Tracks Biotherapeutics, Inc. Ordin to assess how effectively this company generates cash.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $- |
| % of Total Assets | 0% |
| Annual Growth Rate | -4.44% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued - Net Assets Trend (2023–2024)
This chart illustrates how First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued's net assets have evolved over time, based on quarterly financial data. Explore First Tracks Biotherapeutics, Inc. Ordin strategic investment ratio to see how much of total assets are deployed in long-term investments.
Annual Net Assets for First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued (2023–2024)
The table below shows the annual net assets of First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued from 2023 to 2024. For live valuation and market cap data, see TRAXV stock market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $391.60 Million | -4.45% |
| 2023-12-31 | $409.85 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 0.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $391.60 Million | 100.00% |
| Total Equity | $391.60 Million | 100.00% |
First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued Competitors by Market Cap
The table below lists competitors of First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Kambi Group PLC Series B
IL:0EAW
|
$559.27 Million |
|
Algoma Steel Group Inc
TO:ASTL
|
$559.44 Million |
|
Hunan Lead Power Dazhi Technology Inc Co
SHE:300530
|
$559.60 Million |
|
Wuxi Double Elephant Micro Fibre Material Co Ltd
SHE:002395
|
$559.67 Million |
|
Fujian Minfa Aluminium Co Ltd
SHE:002578
|
$559.02 Million |
|
Shandong Lipeng Co Ltd
SHE:002374
|
$558.98 Million |
|
Inner Mongolia North Hauler Joint Stock Co Ltd
SHG:600262
|
$558.97 Million |
|
EXPLOS. PROD. CHIM.EO 31
F:9Z50
|
$558.92 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 409,849,000 to 391,596,000, a change of -18,253,000 (-4.5%).
- Net loss of 163,705,000 reduced equity.
- Other factors increased equity by 145,452,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-163.71 Million | -41.8% |
| Other Changes | $145.45 Million | +37.14% |
| Total Change | $- | -4.45% |
Book Value vs Market Value Analysis
This analysis compares First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.43x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2023-12-31 | $11.79 | $16.09 | x |
| 2024-12-31 | $11.27 | $16.09 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -41.80%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.13x
- Recent ROE (-41.80%) is below the historical average (-33.85%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2023 | -25.90% | 0.00% | 0.00x | 1.08x | $-147.13 Million |
| 2024 | -41.80% | 0.00% | 0.00x | 1.13x | $-202.86 Million |
Industry Comparison
This section compares First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $60,677,567
- Average return on equity (ROE) among peers: -58.27%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued (TRAXV) | $- | -25.90% | N/A | $559.11 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $86.88 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $1.60 Billion |
| Abeona Therapeutics Inc (ABEO) | $42.37 Million | -200.47% | 0.88x | $323.66 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $225.18 Million | -44.68% | 0.02x | $183.46 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $179.13 Million | -57.56% | 0.19x | $804.47 Million |
| Arbutus Biopharma Corp (ABUS) | $203.00 Million | -189.21% | 0.36x | $854.72 Million |
| ABVC Biopharma Inc (ABVC) | $60.67K | -43.96% | 0.04x | $27.18 Million |
| Abivax SA American Depositary Shares (ABVX) | $56.72 Million | -25.23% | 0.07x | $9.73 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $-52.67 Million | 0.00% | 0.00x | $3.63 Billion |
About First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued
First Tracks Biotherapeutics, Inc. operates as a clinical-stage biotechnology company developing antibody therapeutics that modulate immune pathways implicated in autoimmune and inflammatory diseases. First Tracks Biotherapeutics, Inc. was formerly known as Biopharma Co., Inc. and changed its name to First Tracks Biotherapeutics, Inc. in February 2026. First Tracks Biotherapeutics, Inc. was incor… Read more